Vaughan Nelson Investment Management L.P. acquired a new position in Celgene Co. (NASDAQ:CELG) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 3,825 shares of the biopharmaceutical company’s stock, valued at approximately $558,000.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. raised its position in Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after acquiring an additional 3,084,227 shares during the period. Vanguard Group Inc. raised its position in shares of Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares during the period. State Street Corp raised its position in shares of Celgene by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after purchasing an additional 723,844 shares during the period. Jennison Associates LLC raised its position in shares of Celgene by 1.2% in the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after purchasing an additional 156,864 shares during the period. Finally, FMR LLC raised its position in shares of Celgene by 5.9% in the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after purchasing an additional 697,250 shares during the period. 79.84% of the stock is currently owned by institutional investors and hedge funds.

Celgene Co. (NASDAQ:CELG) opened at $106.33 on Monday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a market cap of $83,720.00, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 0.84 and a beta of 1.77.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the previous year, the company earned $1.58 EPS. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. sell-side analysts expect that Celgene Co. will post 6.68 earnings per share for the current year.

Several analysts have recently issued reports on CELG shares. BMO Capital Markets boosted their price target on shares of Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, November 17th. Oppenheimer reissued a “buy” rating and issued a $170.00 price target on shares of Celgene in a research report on Friday, October 20th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a research report on Monday, October 23rd. Cann reissued a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley raised shares of Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $135.43.

TRADEMARK VIOLATION WARNING: “3,825 Shares in Celgene Co. (CELG) Acquired by Vaughan Nelson Investment Management L.P.” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://theolympiareport.com/2017/12/25/3825-shares-in-celgene-co-celg-acquired-by-vaughan-nelson-investment-management-l-p.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.